Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care
Annals of Oncology · 2026-05 · 37 (5) · 579-582
DOI: 10.1016/j.annonc.2026.02.005 ↗Kurz gefasst
Editorial in der Zeitschrift Annals of Oncology, 2026-05. Verfasst von R Sacks und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA. Die Arbeit nennt 23 Literaturangaben. Gefördert von: NCI NIH HHS, National Center for Advancing Translational Sciences, National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.
- Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA. Electronic address: Shipra.gandhi@emory.edu.
Förderung
- NCI NIH HHS
- National Center for Advancing Translational Sciences
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Sacks, R., & Gandhi, S. (2026). Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care. Annals of Oncology, 37(5), 579-582. https://doi.org/10.1016/j.annonc.2026.02.005
Vancouver
Sacks R, Gandhi S. Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care. Annals of Oncology. 2026;37(5):579-582. doi:10.1016/j.annonc.2026.02.005
BibTeX
@article{Sacks2026,
author = {Sacks, R and Gandhi, S},
title = {Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care},
journal = {Annals of Oncology},
year = {2026},
volume = {37},
number = {5},
pages = {579--582},
doi = {10.1016/j.annonc.2026.02.005}
}
EUVIMED